Business Context and Reporting Period
Company: MaxCyte, Inc. (MXCT)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2024
Business Overview: MaxCyte is a global life sciences company focused on cell engineering technologies, specifically Flow Electroporation, to advance cell and gene therapies. The company generates revenue through the sale and lease of instruments, consumables, and strategic platform licenses (SPLs) with biopharmaceutical partners.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $8,164 | $8,004 | $29,934 | $25,623 |
| Gross Profit | $6,236 | $7,211 | $25,115 | $22,454 |
| Gross Margin | 76% | 90% | 84% | 88% |
| Operating Loss | $(14,053) | $(13,952) | $(38,296) | $(40,203) |
| Net Loss | $(11,557) | $(11,251) | $(30,458) | $(32,645) |
| Net Loss Per Share (Basic/Diluted) | $(0.11) | $(0.11) | $(0.29) | $(0.32) |
| Cash and Cash Equivalents | $36,958 | $46,506 (Dec 31, 2023) | N/A | |
| Short-term Investments | $116,874 | $121,782 (Dec 31, 2023) | N/A | |
| Total Assets | $248,612 | $268,274 (Dec 31, 2023) | N/A | |
| Accumulated Deficit | $(206,256) | $(175,798) (Dec 31, 2023) | N/A |
Liquidity: As of September 30, 2024, the company held $36.96 million in cash and cash equivalents and $116.87 million in short-term investments. The company reported no debt obligations.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 2% in Q3 2024 ($8.16M) compared to Q3 2023 ($8.00M). For the nine months ended September 30, revenue grew 17% to $29.93M from $25.62M.
- Revenue Composition:
- Q3: Core revenue increased 23% driven by a 54% increase in disposables revenue ($3.43M vs $2.23M). This was offset by a 98% decrease in program-related milestone revenue ($24K vs $1.4M) due to the variability of clinical milestone achievements.
- 9M: Program-related revenue increased 104% ($6.03M vs $2.96M), contributing significantly to the year-to-date growth.
- Gross Margin Compression: Q3 gross margin declined to 76% from 90% in the prior year. This was primarily due to higher cost of goods sold (up 143%) driven by increased disposable sales volume, higher inventory reserves, and lower absorption of manufacturing overhead.
- Operating Expenses:
- R&D: Decreased 15% in Q3 ($5.32M) and 2% in 9M ($17.61M), largely due to reduced stock-based compensation.
- Sales & Marketing: Decreased 12% in Q3 ($6.21M) but increased 2% in 9M ($20.19M).
- G&A: Increased 14% in Q3 ($7.75M) and 2% in 9M ($22.49M), driven by higher legal fees and stock-based compensation.
- Cash Flow: Net cash used in operating activities improved to $19.8M for the nine months ended September 30, 2024, compared to $22.7M in the prior year period.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue incurring net losses as it invests in sales force expansion, manufacturing scaling, and R&D. The company believes its current cash, cash equivalents, and short-term investments are sufficient to fund operations for at least the next 12 months.
- Strategic Developments: The company signed six new Strategic Platform License (SPL) agreements in the first three quarters of 2024. It expects revenue to grow as partners advance clinical programs and as the installed base of leased instruments increases.
- Listing Strategy: MaxCyte is evaluating the cancellation of its admission from the AIM (London Stock Exchange) to concentrate trading on Nasdaq. This decision is subject to shareholder approval and could impact liquidity and share price volatility during the transition.
- Risks:
- Customer Concentration: One customer represented 30% of revenue in Q3 2024; two customers represented 32% of revenue for the nine months ended September 30, 2024.
- Revenue Variability: Program-related revenue is subject to significant variability based on the timing of clinical milestones achieved by partners.
- Competition: The market for non-viral delivery is competitive; the introduction of GMP-grade platforms by competitors could lead to price pressure.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $153.8M in liquid assets (cash + short-term investments) against the current burn rate of approximately $10M per quarter in operating cash outflows.
- Milestone Revenue Timing: Assess the sustainability of revenue growth given the high volatility of program-related milestone revenue (down 98% in Q3, up 104% in 9M).
- Gross Margin Trends: Monitor the impact of increasing disposable sales volume on gross margins, as higher COGS associated with disposables may continue to pressure margins compared to high-margin milestone revenue.
- Customer Concentration: Review the dependency on top customers (30% of Q3 revenue from a single client) and the risk of contract renewals or delays.
- AIM Delisting: Track the progress of the potential delisting from AIM and its potential impact on shareholder liquidity and stock price.